Wang Jianying, Leng Jinchang, Sun Xiaowei, Peng Kun, Ma Xaojuan, Huang Shiqin, Wang Fang
Department of Infomation, Medical Supplies Center of PLA General Hospital, Beijing 100039, China.
Department of Pharmacy, Medical Supplies Center of PLA General of PLA General Hospital, Beijing 100039, China.
Evid Based Complement Alternat Med. 2022 Aug 26;2022:2597173. doi: 10.1155/2022/2597173. eCollection 2022.
With the development and popularity of percutaneous coronary intervention (PCI), ischemia-reperfusion injury (IRI) has attracted more and more clinical attention. Reperfusion arrhythmia (RA), one of the common manifestations during and after PCI, can affect the postoperative cardiac function of patients with acute myocardial infarction (AMI). Therefore, effective intervention on RA has important clinical significance. This study observed the effect of amiodarone on reperfusion arrhythmia (RA) after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) and explored its possible mechanism. The results showed that amiodarone had good clinical efficacy in the prevention of RA in patients with AMI after PCI, and it could reduce the levels of serum IL-6, hs-CRP, CK-MB, and cTnI in patients and reduce the damage caused by reperfusion, thereby reducing the occurrence of RA.
随着经皮冠状动脉介入治疗（PCI）的发展与普及，缺血再灌注损伤（IRI）已引起越来越多的临床关注。再灌注心律失常（RA）是PCI术中及术后的常见表现之一，可影响急性心肌梗死（AMI）患者的术后心功能。因此，对RA进行有效干预具有重要的临床意义。本研究观察了胺碘酮对急性心肌梗死（AMI）患者经皮冠状动脉介入治疗（PCI）后再灌注心律失常（RA）的影响，并探讨其可能机制。结果显示，胺碘酮对预防AMI患者PCI术后RA具有良好的临床疗效，可降低患者血清IL-6、hs-CRP、CK-MB及cTnI水平，减轻再灌注造成的损伤，从而减少RA的发生。
